TESCENDO
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

TESCENDO Trademark

Serial Number: 98044695

TESCENDO is a trademark filed by The Board of Regents of The University of Texas System on June 15, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

The Board of Regents of The University of Texas System (257 trademarks)

201 West 7th Street
Austin, TX 78701

Entity Type: 14

Trademark Details

Filing Date

June 15, 2023

Registration Date

Not Registered

Published for Opposition

November 5, 2024

Goods & Services

Custom manufacturing of pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; manufacturing of cell therapy platforms for others

Cells for medical or clinical use; pharmaceutical preparations and therapeutic agents for the treatment of cancer, infectious diseases, autoimmune and inflammatory conditions, and genetic diseases and non-genetic endocrine diseases, degenerative diseases, and aging disorders; therapeutic kits comprised of biological and pharmaceutical preparations for use in treatment and therapy for cancer, infectious diseases, autoimmune and inflammatory conditions, and genetic diseases and non-genetic endocrine diseases, degenerative diseases, and aging disorders; test kits for diagnostic preparations for medical purposes comprised of medical diagnostic reagents and assays for testing of body fluids and also containing a sample preparation device for medical diagnostic uses; T-cell receptors expressed on the cell for use in connection with diagnosing and treating cancer, infectious diseases, autoimmune and inflammatory conditions, and genetic diseases and non-genetic endocrine diseases, degenerative diseases, and aging disorders; diagnostic reagents for medical clinical use for treatment of cancer; cell culture kits for medical use primarily comprised of imaging and detection agents for diagnosing and monitoring cancer, and also containing a diagnostic apparatus for medical purposes used in medical laboratories for testing cancer cells; medical testing and treatment product kits primarily comprised of cells for diagnosing and treating cancer, infectious diseases, autoimmune and inflammatory conditions, and genetic diseases and non-genetic endocrine diseases, degenerative diseases, and aging disorders

Reagents for scientific and research purposes, drug discovery research and scientific development, and biological and pharmaceutical reagents, for scientific and research purposes, for use in the manufacturing process of cell therapy platforms; diagnostic reagents for scientific clinical use for treatment of cancer

Medical services; medical services, namely, cellular immunotherapy treatments; medical services, namely, human cancer treatment; providing medical information relating to immunotherapy; providing cancer therapy advice and consultancy

Medical and scientific research services; medical laboratory services; providing information on medical and scientific research in the field of oncology; compiling and analyzing data for research purposes in the field of oncology; consulting in the field of medical and scientific research

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 21, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 21, 2025 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 17, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 5, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 5, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 16, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 24, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 15, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 15, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 15, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 15, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 7, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 7, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
May 3, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
May 3, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 7, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 7, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 7, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 31, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 19, 2023 NWOS
NEW APPLICATION ENTERED
Jun 19, 2023 NWAP